The Eurostars Project OptiStim: Optimal Neurostimulation for the Treatment of Chronic Headaches was approved and started on April 1, 2022.
Z43 partner ZMT Zurich MedTech AG and Salvia BioElectronics B.V. join forces on the OptiStim project to develop a unique implant as an effective therapy for both chronic migraine and chronic cluster headache. The project aims to revolutionize therapy by mapping head and neck anatomy across the patient population and creating neuro-functionalized models to optimize (i) electrode design and electrode configuration, (ii) safe placement of the implant, and (iii) treatment parameters through in silico studies and dosimetric measurements.
The Eurostars funding instrument will support OptiStim for 30 months. This is a joint programme co-funded by EUREKA member countries and by the European Commission. specifically focused on the development of rapidly marketable innovative products, processes and services to improve quality of life.